This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
18 Apr 2012

Quantum Genomics Begins Phase-I Study with QGC001 for Hypertension

Phase-I clinical testing is underway for QGC001, a first-in-class APA inhibitor for the treatment of hypertension.

Biopharmaceutical company Quantum Genomics has initiated a phase-I clinical trial involving its lead compound, QGC001.

 

The therapy is designed to treat hypertension by inhibiting an enzyme called aminopeptidase A (APA) in the brain.

 

It is the first APA inhibitor to reach the clinical stage and will first be tested in healthy volunteers to assess its safety, tolerability and pharmacokinetics.

 

Lionel Segard, chief executive officer of Quantum Genomics, described the study as a "major milestone" for the company.

 

"QGC001 is the first representative of a new class of antihypertensive drugs that may improve the con

Related News